Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2886721 in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
NL-OMON39447Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ly2886721 in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change in cerebrospinal fluid amyloid beta 1-40 concentration and Change in cerebrospinal fluid amyloid beta 1-42 concentration. Started Dec 2012; status: active, not recruiting.
02
Drugs
ly2886721
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NL-OMON39447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39447.